Psychiatrist Dr Tiago Reis Marques discusses what new research findings on ketamine mean for treatment-resistant mental conditions such as major depressive disorder.
The Multidisciplinary Association for Psychedelic Studies (MAPS) has received funding of $1.5m from Wasana Health in a first-of-its-kind collaboration to accelerate research into MDMA-assisted therapy for...
A new, pooled analysis has found that single-dose, clinical administration of LSD is safe in regards to acute psychological and physical harm in healthy subjects.
The first patient has received a dose of psilocybin in the world’s first trial investigating psilocybin as a treatment for a rare and debilitating headache disorder...
Novel analogues of the psychedelic compound 5-MeO-DMT have shown demonstrable safety in preclinical results.
The first-ever authorised export of GMP-compliant natural psilocybin into the US has been completed.
PharmaDrug Inc.
Cybin has filed two international patent applications to support its psychedelic research phases programmes.
Awakn Life Sciences will be carrying out the first-ever study investigating the use of ketamine treatment for gambling addiction, using psychedelic-assisted psychotherapy.
Mydecine Innovations Group has signed a five-year psychedelic research agreement with Johns Hopkins University School of Medicine.